XML 15 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Net sales $ 545,138 $ 534,141 $ 1,672,568 $ 1,538,858
Cost of goods sold 258,422 235,133 781,982 696,412
Gross profit 286,716 299,008 890,586 842,446
Selling, general and administrative expense 201,196 198,169 620,751 605,060
Research and Development Expense 49,245 62,077 146,122 174,116
Segment profit (loss) 36,275 38,762 123,713 63,270
Interest expense 6,064 5,872 17,823 17,233
Foreign exchange (gains) losses, net 672 3,363 1,911 7,668
Unrealized Gain on Securities (318,007) 0 (1,420,339) 0
Nonoperating Income (Expense) 2,585 1,061 29,588 13,486
Income before income taxes 350,131 30,588 1,553,906 51,855
(Provision) benefit for income taxes (80,805) (8,521) (359,763) (12,340)
Net income attributable to Bio-Rad $ 269,326 $ 22,067 $ 1,194,143 $ 39,515
Basic earnings per share:        
Net income per share basic attributable to Bio-Rad $ 9.02 $ 0.74 $ 40.04 $ 1.33
Weighted average common shares - basic 29,863 29,660 29,822 29,618
Diluted earnings per share:        
Net income per share diluted attributable to Bio-Rad $ 8.89 $ 0.73 $ 39.50 $ 1.32
Weighted average common shares - diluted 30,292 30,052 30,234 29,994